Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) EBT Margin (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed EBT Margin for 12 consecutive years, with 88.63% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin fell 1173.0% year-over-year to 88.63%, compared with a TTM value of 99.67% through Sep 2025, down 19583.0%, and an annual FY2024 reading of 85.41%, up 3405.0% over the prior year.
  • EBT Margin was 88.63% for Q3 2025 at Arcadia Biosciences, down from 34.43% in the prior quarter.
  • Across five years, EBT Margin topped out at 671.81% in Q4 2023 and bottomed at 644.32% in Q1 2021.
  • Average EBT Margin over 5 years is 91.78%, with a median of 98.06% recorded in 2022.
  • The sharpest move saw EBT Margin soared 314085bps in 2021, then crashed -100350bps in 2024.
  • Year by year, EBT Margin stood at 373.53% in 2021, then skyrocketed by 105bps to 17.58% in 2022, then surged by 3721bps to 671.81% in 2023, then tumbled by -149bps to 331.69% in 2024, then skyrocketed by 73bps to 88.63% in 2025.
  • Business Quant data shows EBT Margin for RKDA at 88.63% in Q3 2025, 34.43% in Q2 2025, and 44.17% in Q1 2025.